Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Lusutrombopag (Mulpleta) is an oral thrombopoietin receptor agonist used for treating thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a procedure. It effectively increases platelet counts, reduces the need for perioperative platelet transfusions, and decreases bleeding events.
• Two studies were reviewed, which provided detailed information on Mulpleta's efficacy, safety, and comparison with other thrombopoietin receptor agonists.
• Compared to placebo treatment, lusutrombopag significantly increased platelet counts and reduced the necessity for pre-procedure platelet transfusion. The risk of bleeding was also lower compared to placebo treatments.
• When compared against other TPO-RAs such as avatrombopag, eltrombopag, romiplostim, and recombinant human thrombopoietin (rhTPO), both Mulpleta and avatrombopag displayed superior response in terms of increasing platelet counts. However, adverse events were slightly higher in patients receiving other treatments than those receiving Mulpleta or placebo.
• In terms of population types considered during these studies, adult patients suffering from chronic liver disease facing severe thrombocytopenia formed the primary focus group, indicating that this drug has particular effectiveness within this subgroup.
• It can be concluded that lusutrombopag presents itself as a safe, effective treatment option especially when considering its comparative analysis with other TPO-RAs due to its superior efficacy outcomes along with having the lowest risk associated with bleeding among all drugs tested under the same class.